Gottlieb: ACA's expansion of 340B program hurts cancer patients

The 340B drug discount program, which will grow under the Affordable Care Act, has hospitals snapping up oncology practices, but incentivizing hospitals to provide more prescription drugs isn't in the best interest of patients, Dr. Scott Gottlieb writes. "One of the rationales behind the Affordable Care Act was that the law would end the gimmicks that distort incentives and drive up costs. In the case of the 340B program and its effect on cancer treatment, the law has only further distorted an already expensive gimmick," Gottlieb writes.

View Full Article in:

Wall Street Journal (tiered subscription model), The